On the chart you can see the default numbers in dynamics for Eris Lifesciences Limited (ERIS.NS). Companys revenue shows the average of 8937.308 M which is 0.127 % gowth. The average gross profit for the whole period is 7297.222 M which is 0.122 %. The average gross profit ratio is 0.820 %. The net income growth for the company last year performance is -0.059 % which equals 0.173 % % on average for the whole company history.,
Diving into the fiscal trajectory of Eris Lifesciences Limited, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.238. In the realm of current assets, ERIS.NS clocks in at 7647.22 in the reporting currency. A significant portion of these assets, precisely 892.43, is held in cash and short-term investments. This segment shows a change of -0.496% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 68.77, if any, in the reporting currency. This indicates a difference of -98.366% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 6834.21 in the reporting currency. This figure signifies a year_over_year change of 11.455%. Shareholder value, as depicted by the total shareholder equity, is valued at 21959.88 in the reporting currency. The year over year change in this aspect is 0.151%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 2966.95, with an inventory valuation of 1314.35, and goodwill valued at 3318.49, if any. The total intangible assets, if present, are valued at 18805.96. Account payables and short-term debt are 1247.69 and 1932.9, respectively. The total debt is 8767.11, with a net debt of 8206.89. Other current liabilities amount to 217.22, adding to the total liabilities of 14466.51. Lastly, the referred stock is valued at 21930.12, if it exists.
The financial landscape of Eris Lifesciences Limited has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.264. The company recently extended its share capital by issuing 22.78, marking a difference of 0.044 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -9821010000.000 in the reporting currency. This is a shift of 2.073 from the previous year. In the same period, the company recorded 1170.88, 243.72, and -3500, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -999.11 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 7879.36, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Eris Lifesciences Limited's revenue saw a change of 0.112% compared with the previous period. The gross profit of ERIS.NS is reported to be 13094.66. The company's operating expenses are 8898.08, showing a change of 38.967% from the last year. The expenses for depreciation and amortization are 1170.88, which is a 0.810% change from the last accounting period. Operating expenses are reported to be 8898.08, which shows a 38.967% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.104% year-over-year growth. The operating income is 4216.63, which shows a -0.007% change when compared to the previous year. The change in the net income is -0.059%. The net income for the last year was 3821.58.
